Ritwik Bhaduri

2022 · Mayo Clinic Proceedings: Innovations, Quality & Outcomes

Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19

Deblina Raychaudhuri, Purbita Bandopadhyay, Ranit D'Rozario, Jafar Sarif, Yogiraj Ray, Shekhar Ranjan Paul, Praveen Singh, Kausik Chaudhuri, Ritwik Bhaduri, Rajesh Pandey, et al.

Journal article

Abstract

A series of subclass analyses were performed on previously published outcome data and accompanying clinical metadata from a completed randomized controlled trial (CTRI/2020/05/025209) assessing clinical and immunological benefits of convalescent plasma therapy (CPT). Although the primary clinical outcomes were not significantly different in the RCT across all age groups, significant immediate mitigation of hypoxia, reduction in hospital stay, and significant survival benefit were registered in younger patients (under 67 years of age) with severe COVID-19 and acute respiratory distress syndrome on receiving CPT. In addition to neutralizing the antibody content of convalescent plasma, its anti-inflammatory proteome, by attenuation of the systemic cytokine deluge, significantly contributed to the clinical benefits of CPT. Subgroup analyses revealed that clinical benefits of CPT in severe COVID-19 are linked to the anti-inflammatory protein content of convalescent plasma apart from the anti-SARS-CoV-2 neutralizing antibody content.

BibTeX

@article{raychaudhuri2022clinical,
  title={Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19},
  author={Deblina Raychaudhuri and Purbita Bandopadhyay and Ranit D'Rozario and Jafar Sarif and Yogiraj Ray and Shekhar Ranjan Paul and Praveen Singh and Kausik Chaudhuri and Ritwik Bhaduri and Rajesh Pandey and others},
  journal={Mayo Clinic Proceedings: Innovations, Quality & Outcomes},
  year={2022},
  doi={10.1016/j.mayocpiqo.2022.09.001},
  abstract={A series of subclass analyses were performed on previously published outcome data and accompanying clinical metadata from a completed randomized controlled trial assessing clinical and immunological benefits of convalescent plasma therapy (CPT). Although the primary clinical outcomes were not significantly different in the RCT across all age groups, significant immediate mitigation of hypoxia, reduction in hospital stay, and significant survival benefit were registered in younger patients with severe COVID-19 and acute respiratory distress syndrome on receiving CPT. Subgroup analyses revealed that clinical benefits of CPT in severe COVID-19 are linked to the anti-inflammatory protein content of convalescent plasma apart from the anti-SARS-CoV-2 neutralizing antibody content.}
}